PBLA Panbela Therapeutics Dashboard

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

Company profile

Ticker

PBLA

Exchange

NASDAQ

Website

panbela.com

CEO

Michael Cullen

Incorporated

Delaware

Location

Minnesota

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Computer Systems Design Services

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.

SEC CIK

0001029125

Corporate docs

Articles of Incorporation & Bylaws

PBLA stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Panbela Therapeutics Files For International Patent Titled 'DOSING REGIMENS AND METHODS FOR TREATING CANCER'

29 Jul 21

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021150559&PN=31978

12 Health Care Stocks Moving In Wednesday's After-Market Session

28 Jul 21

Gainers

Stocks That Hit 52-Week Lows On Thursday

15 Jul 21

During the morning session on Thursday, 152 stocks hit new 52-week lows.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

8 Jul 21

72 Biggest Movers From Yesterday

1 Jul 21

Press releases

Pro users get this 30m faster

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

29 Jul 21

New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors

Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET

7 Jul 21

MINNEAPOLIS, July 07, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today

PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

2 Jul 21

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA) (the "Company" or "Panbela"), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of

PANBELA THERAPEUTICS INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON STOCK TO $10.0 MILLION

30 Jun 21

PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

29 Jun 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart PBLA financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	8.1M	8.1M	8.1M	8.1M	8.1M	8.1M
Cash burn (monthly)	308K	(positive/no burn)	749.33K	579.08K	655K	391.58K
Cash used (since last report)	1.26M	n/a	3.06M	2.37M	2.68M	1.6M
Cash remaining	6.84M	n/a	5.04M	5.73M	5.42M	6.5M
Runway (months of cash)	22.2	n/a	6.7	9.9	8.3	16.6

Beta Read what these cash burn values mean

Recent insider trades

PBLA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
25 May 21	Michael T. Cullen	Common Stock	Grant	Aquire A	No	No	0	4,316	0	216,811
25 May 21	Michael T. Cullen	Stock Option Common Stock	Grant	Aquire A	No	No	4.17	12,368	51.57K	12,368
25 May 21	Schaffer Paul W.	Common Stock	Grant	Aquire A	No	No	0	4,316	0	166,671
25 May 21	Schaffer Paul W.	Stock Option Common Stock	Grant	Aquire A	No	No	4.17	12,368	51.57K	12,368
25 May 21	Mathiesen Jeffrey S	Common Stock	Grant	Aquire A	No	No	0	4,316	0	10,191
25 May 21	Mathiesen Jeffrey S	Stock Option Common Stock	Grant	Aquire A	No	No	4.17	12,368	51.57K	12,368
25 May 21	Schemel Donald Robert	Common Stock	Grant	Aquire A	No	No	0	4,316	0	96,619
25 May 21	Schemel Donald Robert	Stock Option Common Stock	Grant	Aquire A	No	No	4.17	12,368	51.57K	12,368
25 May 21	Fratamico Arthur	Common Stock	Grant	Aquire A	No	No	0	4,316	0	9,615
25 May 21	Fratamico Arthur	Stock Option Common Stock	Grant	Aquire A	No	No	4.17	12,368	51.57K	12,368

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

PBLA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	5	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acquire, Additionally, American, analyzed, ASCO, assessment, baseline, begun, blood, bone, CA, care, cell, checkpoint, chemotherapy, collaboration, conclusion, conference, conferred, country, cutoff, cycle, detachment, distribution, dosage, DSMB, efficacy, Eleven, entered, flat, GI, headcount, hereof, history, hold, India, ingredient, integral, justify, learn, light, Marker, marrow, Medicine, middle, monotherapy, neuropathy, Oncology, ophthalmologic, original, Panbela, PD, peripheral, preliminary, procure, regimen, remotely, responding, restarted, retinal, retinopathy, School, screening, separated, showed, social, Society, successfully, suggest, supplier, toxicity, visual, withhold, wrapping

Removed: Aid, amendment, amortization, amortized, annum, BioPharma, capitalized, charged, cohort, commenced, continuation, converted, DCR, deficit, discontinue, discount, executed, extend, hand, Institute, issuable, limitation, loan, mature, maturity, modification, monthly, payable, payroll, PDA, portion, PPP, program, Promising, promissory, Protection, PRs, reached, recommended, Relief, Security, Spring, Sun, therapy, unchanged, unpaid, unsecured, untreated, warrant, week

From filing 10-Q 2021 Q1